EP1095657A3 - Compositions for the regulation of cytokine activity - Google Patents
Compositions for the regulation of cytokine activity Download PDFInfo
- Publication number
- EP1095657A3 EP1095657A3 EP00123134A EP00123134A EP1095657A3 EP 1095657 A3 EP1095657 A3 EP 1095657A3 EP 00123134 A EP00123134 A EP 00123134A EP 00123134 A EP00123134 A EP 00123134A EP 1095657 A3 EP1095657 A3 EP 1095657A3
- Authority
- EP
- European Patent Office
- Prior art keywords
- host
- compositions
- sulfated
- acetylated
- substances
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cosmetics (AREA)
- Orthopedics, Nursing, And Contraception (AREA)
- Saccharide Compounds (AREA)
Abstract
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US97475092A | 1992-11-10 | 1992-11-10 | |
US974750 | 1992-11-10 | ||
US9673993A | 1993-07-23 | 1993-07-23 | |
US96739 | 1993-07-23 | ||
EP94901394A EP0669827B1 (en) | 1992-11-10 | 1993-11-09 | Compositions for the regulation of cytokine activity |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP94901394A Division EP0669827B1 (en) | 1992-11-10 | 1993-11-09 | Compositions for the regulation of cytokine activity |
Publications (3)
Publication Number | Publication Date |
---|---|
EP1095657A2 EP1095657A2 (en) | 2001-05-02 |
EP1095657A3 true EP1095657A3 (en) | 2004-02-25 |
EP1095657B1 EP1095657B1 (en) | 2007-01-10 |
Family
ID=26792027
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP94901394A Expired - Lifetime EP0669827B1 (en) | 1992-11-10 | 1993-11-09 | Compositions for the regulation of cytokine activity |
EP00123134A Expired - Lifetime EP1095657B1 (en) | 1992-11-10 | 1993-11-09 | Compositions for the regulation of cytokine activity |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP94901394A Expired - Lifetime EP0669827B1 (en) | 1992-11-10 | 1993-11-09 | Compositions for the regulation of cytokine activity |
Country Status (18)
Country | Link |
---|---|
EP (2) | EP0669827B1 (en) |
JP (1) | JPH08506322A (en) |
CN (1) | CN1093904A (en) |
AT (1) | ATE201327T1 (en) |
AU (2) | AU699624B2 (en) |
CA (1) | CA2149116A1 (en) |
DE (2) | DE69334102T2 (en) |
FI (1) | FI952267A (en) |
HR (1) | HRP931389A2 (en) |
HU (1) | HUT70945A (en) |
IL (1) | IL107563A (en) |
NO (1) | NO951822L (en) |
NZ (1) | NZ258367A (en) |
PL (1) | PL309001A1 (en) |
SI (1) | SI9300586A (en) |
TW (1) | TW257678B (en) |
WO (1) | WO1994011006A1 (en) |
YU (1) | YU71393A (en) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6750207B1 (en) | 1992-05-01 | 2004-06-15 | Yeda Research And Development Co. Ltd. | Compositions for the regulation of cytokine activity |
HUT70945A (en) * | 1992-11-10 | 1995-11-28 | Yeda Res & Dev | Compositions for the regulation of cytokine activity contg. oligosaccharides and process to prepare them |
US6846917B2 (en) | 2001-01-23 | 2005-01-25 | Massachusetts Institute Of Technology | Solid- and solution-phase synthesis of heparin and other glycosaminoglycans |
US7285536B2 (en) | 2001-12-05 | 2007-10-23 | Yeda Research And Development Co., Ltd. | Anti-cancer therapeutic compounds |
ITMI20021294A1 (en) * | 2002-06-12 | 2003-12-12 | Inalco Spa | O-SULPHATED BACTERIAL POLYSACCHARIDES AND THEIR USE |
US20060293275A1 (en) * | 2004-03-29 | 2006-12-28 | Toshikazu Nakamura | Hgf production accelerator containing heparin-like oligosaccharide |
ITMI20091445A1 (en) * | 2009-08-07 | 2011-02-08 | Inalco S P A A Socio Unico | SEMI-SYNTHETIC DERIVATIVES OF K5 POLISACCARIDE FOR THE PREVENTION AND TREATMENT OF TISSUE DAMAGE ASSOCIATED WITH ISCHEMIA AND / OR REPERFUSION |
PL2747565T3 (en) | 2011-09-08 | 2017-09-29 | Novozymes Bioag A/S | Seed treatment methods |
AU2012308443B2 (en) | 2011-09-14 | 2017-05-04 | Novozymes Bioag A/S | Use of lipochito-oligosaccharides and/or chito oligosaccharides in combination with phosphate-solubilizing microorganisms to enhance plant growth |
MX351416B (en) | 2011-09-23 | 2017-10-13 | Novozymes Bioag As | Chitooligosaccharides and methods for use in enhancing plant growth. |
CN102824352B (en) * | 2011-10-11 | 2013-09-04 | 泸州医学院 | Application of disaccharide compound in preparing anti-tumor medicine |
CN109730006B (en) * | 2019-03-19 | 2022-10-18 | 西华大学 | Method for increasing melanin content in animals |
CN110646557A (en) * | 2019-10-12 | 2020-01-03 | 北京航空航天大学 | Urine metabolic marker of glioblastoma patient carrying IDH gene mutation and application thereof |
WO2021179047A1 (en) | 2020-03-12 | 2021-09-16 | Cullis Hill Sydney David | Treatment for coronavirus infection and associated cytokine toxicity |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0084999A1 (en) * | 1982-01-15 | 1983-08-03 | D.R.O.P.I.C. (Société Civile) | Process for the preparation of organic oligosaccharides, corresponding to fragments of natural muco-polysaccharides, oligosaccharides obtained and their biological applications |
JPH03169821A (en) * | 1989-11-28 | 1991-07-23 | Kissei Pharmaceut Co Ltd | Prostaglandin i2 forming enhancer |
BE1004029A6 (en) * | 1990-11-22 | 1992-09-08 | Mol Omer De | Pharmaceutical compound and pharmaceutical set for the treatment of cancer |
WO1992019249A1 (en) * | 1991-05-02 | 1992-11-12 | Yeda Research And Development Co. Ltd. | Compositions for the prevention and/or treatment of pathological processes |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL61201A (en) * | 1979-10-05 | 1984-09-30 | Choay Sa | Oligosaccharides having no more than 8 saccharide moieties,their obtention from heparin and pharmaceutical compositions containing them |
US4818816A (en) * | 1981-04-28 | 1989-04-04 | Choay, S.A. | Process for the organic synthesis of oligosaccharides and derivatives thereof |
FR2538404B1 (en) * | 1982-12-28 | 1985-08-23 | Anic Spa | |
IT1195497B (en) * | 1983-03-08 | 1988-10-19 | Opocrin Spa | PROCEDURE FOR THE PREPARATION OF OLIGOSACCHARIDIC FRACTIONS EQUIPPED WITH PHARMACOLOGICAL PROPERTIES FOR CHEMICAL DEGRADATION OF HEPARIN |
FR2597484B1 (en) * | 1986-04-17 | 1988-12-23 | Sanofi Sa | GLYCOSAMINOGLYCANS OF THE HEPARIN OR HEPARANE-SULPHATE TYPE WITH ACTIVITY ON CELL DIVISION AND DIFFERENTIATION, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATIONS. |
FR2614026B1 (en) * | 1987-04-16 | 1992-04-17 | Sanofi Sa | LOW MOLECULAR WEIGHT HEPARINS WITH REGULAR STRUCTURE, THEIR PREPARATION AND THEIR BIOLOGICAL APPLICATIONS |
HUT70945A (en) * | 1992-11-10 | 1995-11-28 | Yeda Res & Dev | Compositions for the regulation of cytokine activity contg. oligosaccharides and process to prepare them |
-
1993
- 1993-11-09 HU HU9501373A patent/HUT70945A/en unknown
- 1993-11-09 CA CA002149116A patent/CA2149116A1/en not_active Abandoned
- 1993-11-09 EP EP94901394A patent/EP0669827B1/en not_active Expired - Lifetime
- 1993-11-09 PL PL93309001A patent/PL309001A1/en unknown
- 1993-11-09 AU AU64783/98A patent/AU699624B2/en not_active Ceased
- 1993-11-09 EP EP00123134A patent/EP1095657B1/en not_active Expired - Lifetime
- 1993-11-09 WO PCT/US1993/010868 patent/WO1994011006A1/en active IP Right Grant
- 1993-11-09 DE DE69334102T patent/DE69334102T2/en not_active Expired - Fee Related
- 1993-11-09 DE DE69330252T patent/DE69330252T2/en not_active Expired - Fee Related
- 1993-11-09 JP JP6512329A patent/JPH08506322A/en active Pending
- 1993-11-09 AT AT94901394T patent/ATE201327T1/en not_active IP Right Cessation
- 1993-11-09 AU AU55993/94A patent/AU686581B2/en not_active Ceased
- 1993-11-09 NZ NZ258367A patent/NZ258367A/en unknown
- 1993-11-10 TW TW082109442A patent/TW257678B/zh active
- 1993-11-10 YU YU71393A patent/YU71393A/en unknown
- 1993-11-10 IL IL107563A patent/IL107563A/en not_active IP Right Cessation
- 1993-11-10 CN CN93121328A patent/CN1093904A/en active Pending
- 1993-11-10 HR HR931389A patent/HRP931389A2/en not_active Application Discontinuation
- 1993-11-10 SI SI9300586A patent/SI9300586A/en unknown
-
1995
- 1995-05-09 NO NO951822A patent/NO951822L/en unknown
- 1995-05-10 FI FI952267A patent/FI952267A/en not_active Application Discontinuation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0084999A1 (en) * | 1982-01-15 | 1983-08-03 | D.R.O.P.I.C. (Société Civile) | Process for the preparation of organic oligosaccharides, corresponding to fragments of natural muco-polysaccharides, oligosaccharides obtained and their biological applications |
JPH03169821A (en) * | 1989-11-28 | 1991-07-23 | Kissei Pharmaceut Co Ltd | Prostaglandin i2 forming enhancer |
BE1004029A6 (en) * | 1990-11-22 | 1992-09-08 | Mol Omer De | Pharmaceutical compound and pharmaceutical set for the treatment of cancer |
WO1992019249A1 (en) * | 1991-05-02 | 1992-11-12 | Yeda Research And Development Co. Ltd. | Compositions for the prevention and/or treatment of pathological processes |
Non-Patent Citations (7)
Title |
---|
DATABASE WPI Section Ch Week 199135, Derwent World Patents Index; Class B04, AN 1991-257972, XP002265425 * |
LINHARDT, ROBERT J. ET. AL.: "Oligosaccharide mapping of low-molecular-weight heparins: structure and activity differences", JOURNAL OF MEDICINAL CHEMISTRY, vol. 33, 1906 - 1990, pages 1639 - 1645, XP002265424 * |
NADER, HELENA B. ET AL: "Structural requirements of heparin disaccharides responsible for hemorrhage: reversion of the antihemostatic effect by ATP", FASEB JOURNAL ( 1989 ), 3(12), 2420-4, XP001160861 * |
OKAYAMA, MINORU ET AL: "Purification and characterization of novel heparan sulfate proteoglycans produced by murine erythroleukemia cells in the growing phase", JOURNAL OF BIOLOGICAL CHEMISTRY ( 1991 ), 266(6), 3808-19, XP001174105 * |
RICE K G ET AL: "STUDY OF STRUCTURALLY DEFINED OLIGOSACCHARIDE SUBSTRATES OF HEPARIN AND HEPARAN MONOSULFATE LYASES", CARBOHYDRATE RESEARCH, ELSEVIER SCIENTIFIC PUBLISHING COMPANY. AMSTERDAM, NL, vol. 190, no. 2, 1 July 1989 (1989-07-01), pages 219 - 233, XP000026506, ISSN: 0008-6215 * |
Y. KARIYA ET AL.: "Preparation of unsaturated disaccharides by eliminative cleavage of heparin and heparan sulfate with heparitinases.", COMP. BIOCHEM. PHYSIOL., vol. 103B, no. 2, 1992, pages 473 - 479, XP000561260 * |
YAMADA S ET AL: "ONE- AND TWO-DIMENSIONAL H-NMR CHARACTERIZATION OF TWO SERIES OF SULFATED DISACCHARIDES PREPARED FROM CHONDROITIN SULFATE AND HEPARAN SULFATE/HEPARIN BY BACTERIAL ELIMINASE DIGESTION", JOURNAL OF BIOCHEMISTRY, JAPANESE BIOCHEMICAL SOCIETY, TOKYO, JP, vol. 112, no. 4, 1992, pages 440 - 447, XP001160880, ISSN: 0021-924X * |
Also Published As
Publication number | Publication date |
---|---|
HU9501373D0 (en) | 1995-06-28 |
SI9300586A (en) | 1994-09-30 |
ATE201327T1 (en) | 2001-06-15 |
CA2149116A1 (en) | 1994-05-26 |
NO951822L (en) | 1995-06-29 |
EP0669827A4 (en) | 1996-08-28 |
HUT70945A (en) | 1995-11-28 |
NZ258367A (en) | 1997-02-24 |
AU6478398A (en) | 1998-06-25 |
EP0669827A1 (en) | 1995-09-06 |
HRP931389A2 (en) | 1995-04-30 |
AU686581B2 (en) | 1998-02-12 |
DE69330252T2 (en) | 2002-02-07 |
EP1095657B1 (en) | 2007-01-10 |
PL309001A1 (en) | 1995-09-18 |
JPH08506322A (en) | 1996-07-09 |
AU699624B2 (en) | 1998-12-10 |
YU71393A (en) | 1997-05-28 |
DE69334102D1 (en) | 2007-02-22 |
NO951822D0 (en) | 1995-05-09 |
WO1994011006A1 (en) | 1994-05-26 |
AU5599394A (en) | 1994-06-08 |
FI952267A (en) | 1995-07-10 |
TW257678B (en) | 1995-09-21 |
IL107563A (en) | 2006-12-31 |
IL107563A0 (en) | 1994-02-27 |
DE69330252D1 (en) | 2001-06-28 |
EP1095657A2 (en) | 2001-05-02 |
CN1093904A (en) | 1994-10-26 |
EP0669827B1 (en) | 2001-05-23 |
FI952267A0 (en) | 1995-05-10 |
DE69334102T2 (en) | 2007-10-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1095657A3 (en) | Compositions for the regulation of cytokine activity | |
CA2118121C (en) | Methods and compositions for the treatment of diseases with interferon while reducing side effects | |
NZ251320A (en) | Bis-aromatic alpha,beta-unsaturated ketones, preparation and use in pharmaceutical compositions | |
CA2170047A1 (en) | Androstenone derivative | |
DE69324671D1 (en) | IMPROVED ALPHA INTERFERON COMPOSITION AND METHOD FOR THE PRODUCTION THEREOF FROM LEUKOCYTES OF THE HUMAN PERIPHERAL BLOOD | |
EP0765160A4 (en) | ||
IL107518A0 (en) | Therapeutic and diagnostic compositions comprising purified surface modifiers to prevent particle aggregation during sterilization | |
EP0876143A4 (en) | Tumor necrosis factor alpha (tnf-alpha) inhibiting pharmaceuticals | |
CA2067381A1 (en) | Treatment of hiv infections and compounds useful therein | |
AU4245289A (en) | Psyllium-containing products | |
WO1997028812A3 (en) | Pharmaceutical compositions for biological treatment of infections by enterococcus faecium strains resistant to antibiotics and to vancomycin in particular (vre) | |
CA2037779A1 (en) | Antibiotic ge 2270 factors b1, b2, c1, c2, d1, d2, e and t | |
AU7681091A (en) | Method and medicament for prevention or medication of human leucocyte elastase-mediated pulmonary diseases | |
CA2075926A1 (en) | Hydroquinone amino-acid esters, method of preparation, and pharmaceutical or cosmetic compositions containing them | |
CA2078805A1 (en) | Cytokine Preparation | |
AU6942896A (en) | Use of muteins of wild-type cytokines as immunogens | |
Zicari et al. | Stimulation of macrophages with IFNγ or TNFα shuts off the suppressive effect played by PGE2 | |
RU93054957A (en) | METHOD FOR PRODUCING VEGETABLE BIOLOGICALLY ACTIVE POLYSACCHARIDE | |
WO1998036758A3 (en) | Therapeutic agents containing oxygen anion radicals and the use thereof in the treatment of parkinson's disease | |
Gemmell | Interaction of Clostridium difficile toxin with human polymorphonuclear leukocyte function. | |
Roekke et al. | Endotoxin and cytokines in plasma and clinical manifestations during treatment of septicaemia with imipenem or cefuroxime/metronidazole | |
WO1994008474A3 (en) | Medical food and method of administration | |
RU95113594A (en) | Composition for cytokin activity regulation | |
GR1002969B (en) | Medicinal preparation based on fetal cell suspension, having immune substituting effect and method of treatment of acquired immune deficiency syndrome (HIV infection) with the use of said preparation. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AC | Divisional application: reference to earlier application |
Ref document number: 669827 Country of ref document: EP |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
PUAL | Search report despatched |
Free format text: ORIGINAL CODE: 0009013 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: 7C 07H 11/00 B Ipc: 7A 61K 31/70 A |
|
AK | Designated contracting states |
Kind code of ref document: A3 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
17P | Request for examination filed |
Effective date: 20040825 |
|
AKX | Designation fees paid |
Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
17Q | First examination report despatched |
Effective date: 20050509 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AC | Divisional application: reference to earlier application |
Ref document number: 0669827 Country of ref document: EP Kind code of ref document: P |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20070110 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20070110 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20070110 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REF | Corresponds to: |
Ref document number: 69334102 Country of ref document: DE Date of ref document: 20070222 Kind code of ref document: P |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20070410 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20070421 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20070611 |
|
NLV1 | Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act | ||
ET | Fr: translation filed | ||
RAP2 | Party data changed (patent owner data changed or rights of a patent transferred) |
Owner name: YEDA RESEARCH AND DEVELOPMEMT CO., LTD. |
|
RAP2 | Party data changed (patent owner data changed or rights of a patent transferred) |
Owner name: YEDA RESEARCH AND DEVELOPMENT CO., LTD. |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20071011 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20070110 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20071127 Year of fee payment: 15 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20070411 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20071130 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20081107 Year of fee payment: 16 Ref country code: CH Payment date: 20081117 Year of fee payment: 16 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20081112 Year of fee payment: 16 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20081105 Year of fee payment: 16 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20081109 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20071109 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IE Payment date: 20071113 Year of fee payment: 15 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20081110 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20091109 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20100730 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20091130 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20091130 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20091130 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100601 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20091109 |